Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENSKYCE vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Induction and maintenance of sedation in adult patients undergoing diagnostic or therapeutic procedures
Prevention of pregnancy
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
12 hours (terminal); allows once-daily dosing in most patients
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Fospropofol is rapidly converted to propofol, phosphate, and formaldehyde by alkaline phosphatases (primarily in liver and plasma). Propofol is then metabolized in the liver via glucuronidation (UGT1A9) and hydroxylation (CYP2B6, CYP2C9) to inactive metabolites.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
95% bound to albumin
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.25 L/kg (low, indicates minimal tissue distribution)
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 80% (with interindividual variability)
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
Cr Cl 30-79 m L/min: No adjustment. Cr Cl 15-29 m L/min: Reduce dose to 1 g IV every 8 hours. Cr Cl <15 m L/min: Use 1 g IV every 24 hours; consider alternative therapy.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 1.5 g IV every 8 hours. Child-Pugh C: Use 1 g IV every 12 hours; clinical monitoring recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
WARNING: RISK OF RESPIRATORY DEPRESSION AND NEED FOR RESUSCITATION EQUIPMENT. ENSKYCE should be administered only by personnel trained in the administration of general anesthesia and management of airway emergencies. Resuscitation equipment and drugs must be immediately available. Because of the potential for respiratory depression, patients must be continuously monitored for respiratory function.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Respiratory depression and apnea,Hypotension and bradycardia,Must only be administered by trained anesthesia personnel,Risk of propofol infusion syndrome (with prolonged use),May cause hypotension; correct hypovolemia before administration,Use caution in elderly or debilitated patients,May cause pain on injection,Monitoring of vital signs required
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, soy products, or peanuts (due to excipients),Patients with severe hepatic impairment or lipid metabolism disorders (relative)
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid high-fat, fried, or spicy foods as they may exacerbate gastrointestinal adverse effects; take with or without food; maintain adequate fluid intake to reduce constipation risk; no specific food-drug interactions but alcohol may increase hypoglycemic risk when combined with other antidiabetic drugs.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
No human data available; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded in first trimester; avoid use unless benefit outweighs risk. Second and third trimester: no known fetal risks, but limited data.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
No data on secretion in human milk; M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infants. Weigh benefits against risks.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No established dose adjustments for pregnancy. Pharmacokinetic changes (increased volume of distribution, enhanced clearance) may reduce drug exposure; monitor clinical response and consider dose titration if efficacy wanes.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Start with 2.5 mg once weekly, escalate by 2.5 mg increments every 4 weeks to minimize gastrointestinal intolerance; monitor renal function (e GFR required before initiation); if e GFR <30 m L/min/1.73 m², use 0.5 mg initiation and titrate slowly; switch from subcutaneous semaglutide to ENSKYCE requires same dose but monitor for 4 weeks for GI side effects; thyroid C-cell tumor risk requires baseline calcitonin; do not use in patients with personal or family history of medullary thyroid carcinoma or MEN2.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed; do not change dose or frequency without consulting doctor.,Visual injection aids: inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly.,Most common side effects are nausea, vomiting, diarrhea, and constipation; these may decrease over time.,Avoid alcohol and high-fat meals as they may increase gastrointestinal side effects.,Report symptoms of thyroid tumors: lump in neck, difficulty swallowing, hoarseness.,If severely vomiting or unable to eat/drink, seek medical attention to prevent dehydration and kidney injury.,Do not share pens; store in refrigerator between 36-46°F (2-8°C); protect from light.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENSKYCE vs ALYACEN 1/35, answered by our medical review team.
ENSKYCE is a Oral Contraceptive that works by ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENSKYCE and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENSKYCE is: 2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENSKYCE and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENSKYCE is classified as Category C. No human data available; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded in first trimester; avoid use unless benefit outweighs ris. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.